An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Silverback Therapeutics (Nasdaq: SBTX) announced its participation in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022. CEO Laura Shawver, Ph.D., will deliver a corporate overview on March 9 at 12:50 p.m. ET. Investors can access the live webcast through Silverback's Investor Relations website, with a replay available for 30 days post-event. The biopharmaceutical company focuses on developing targeted therapeutics for cancer and chronic viral infections using its proprietary ImmunoTAC platform.
Positive
None.
Negative
None.
SEATTLE--(BUSINESS WIRE)--
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.
Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, will present a corporate overview on Wednesday, March 9th, 2022, at 12:50 p.m. ET (9:50 a.m. PT). The live webcast of the presentation will be available on Silverback’s Investor Relations website and a replay will be available for 30 days following the event. Members of the Silverback management team will also host investor meetings during the conference.
About Silverback Therapeutics
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.
